Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 68 results for hepatocellular carcinoma

  1. Radiofrequency ablation of hepatocellular carcinoma (IPG2)

    Evidence-based recommendations on radiofrequency ablation of hepatocellular carcinoma. This involves using heat to destroy the part of the liver that contains the cancer.

    Interventional procedures guidance
    Published
    23 July 2003
    View recommendations

    Sections for IPG2

  2. Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

    Interventional procedures guidance
    Published
    23 July 2013
    View recommendations

    Sections for IPG460

  3. Microwave ablation of hepatocellular carcinoma (IPG214)

    Evidence-based recommendations on microwave ablation of hepatocellular carcinoma. This involves using heat from microwave energy to destroy the cancer cells.

    Interventional procedures guidance
    Published
    28 March 2007
    View recommendations

    Sections for IPG214

  4. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896

  5. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

    Clinical guideline
    Last updated
    20 October 2017
    View recommendations

    Sections for CG165

  6. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA153

  7. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

    HealthTech guidance
    Published
    29 August 2012
    View recommendations

    Sections for HTG291

  8. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  9. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation

  10. Transarterial Chemoembolisation for inoperable hepatocellular carcinoma

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    21 February 2018
    View recommendations

    Sections for TA507

  13. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA154

  14. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  15. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development